Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression

Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression

Intermittent androgen suppression (IAS) therapy for prostate cancer patients attempts to maintain the hormone dependence of the tumor cells by cycles alternating between androgen suppression (AS) and treatment cessation till a certain prostate-specific antigen (PSA) threshold is reached. Side effect...

Full description

Bibliographic Details
Main Authors: Gerhard Theyer, Ulrike Olszewski-Hamilton, Gerhard Hamilton
Format: Article
Language:English
Published: MDPI AG 2011-09-01
Series:Cancers
Subjects:
intermittent androgen suppression
prostate cancer
prostate-specific antigen
bone turnover
PINP
Online Access:http://www.mdpi.com/2072-6694/3/3/3601/

Internet

http://www.mdpi.com/2072-6694/3/3/3601/

Similar Items